Insights from the CEOs:
Medidata’s CEO, Anthony Costello, talks with Click Therapeutics’ Founder and CEO David Klein, about Prescription Digital Therapeutics: From Trials to Treatments
Defining a New Standard of Care.
Delivering Better Patient Outcomes.
Digital Therapeutics | Software-Enhanced DrugsTM
Improve patient recruitment, increase patient retention, collect real-world data in real time, and lead to better patient and clinical trial outcomes.
Together, Medidata and Click Therapeutics unify clinical research and patient-centric therapeutic design to support the development of Prescription Digital Therapeutics (PDTs) and Software-Enhanced (SETM) Drug treatments, advancing patient-centric care.
Learn more about Software-Enhanced DrugsTM and Digital Therapeutics
The Future of Medicine is Digital. Medidata and Click Therapeutics can help incorporate Digital Therapeutics into your clinical trials and help bring digital interventions and software-based treatments to market with confidence, backed by decades of proven success in clinical trial execution and DTx development across a wide range of therapeutic areas.
Medicine Just Got a Digital Upgrade
Combine software with pharmacotherapy to create Software-Enhanced Drug™ treatment options, targeting the unique needs of a specific medication to differentiate your portfolio and deliver added clinical benefit to patients.
Evidence-based, high-impact software as medicine.
Click’s platform can target any disease, symptom or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
What is Prescription Drug Use-Related Software?
Learn how the FDA draft guidance clarifies when software can be added to drug labels, and the opportunity for existing and future drugs to digitally upgrade their outcomes with the addition of therapeutic software.
Partners to bring your digital vision into reality
Medicine is shifting toward more proactive, patient-focused care, paving the way for a digital future. Together, Medidata and Click Therapeutics can partner with you to incorporate digital therapeutics into clinical trials and boost outcomes. We can also work with you to upgrade your pipeline and commercial assets into Software-Enhanced DrugTM treatments, which may increase treatment efficacy and feature added clinical benefit claims right in the drug label.
Patients, Pipeline & Promise: Software-Enhanced Drugs
Anthony Costello, Medidata’s CEO, and David Klein, Click Therapeutics Founder and CEO, and a panel of experts discuss why now is the time for you to embrace Software-Enhanced (SE) drugs.
Digital Therapeutics (DTx): Everything You Need to Know
Learn what digital therapeutics are, how they work, who they benefit, where the industry is headed & how they can be integrated into existing drug development.
5 Step to Power Your Pipeline with Digital Therapeutics
Medidata and Click Therapeutics introduce five steps to take when beginning to evaluate your drug pipeline for differentiation with digital therapeutics.
Prescription Digital Therapeutics, from Trials to Treatment: Click Therapeutics’ David Benshoof Klein
Join David and Anthony to explore the vast potential of digital therapeutics for treating everything from migraines to cancer, and how to build solutions that genuinely benefit patients.
Advancing Novel Digital Treatments with the Medidata & Click Therapeutics Partnership
Learn more about how this partnership can open new pipelines of opportunity and drive meaningful advancements in patient care with digital interventions developed and validated through Click’s scientific rigor and Medidata’s clinical trial platform.
Industry Insights
Contact an Expert
Let’s schedule a time to talk.
We’re excited to connect with you about the future of healthcare. Whether you’re interested in digital therapeutics, SE drugs, or have other questions, our team is ready to help.
Please fill out the form, and a Medidata expert will be in touch with you shortly.